A Study Assessing DNA Markers for the Detection of Pancreatic Cancer and Precancer

Overview

About this study

The purpose of this study is to assess DNA markers in pancreatic juice and stool for the detection of pancreatic cancer and precancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Cases
    • Pancreatic cancer (adenocarcinoma)
    • Pancreatic precancer (includes IPMN (Branch-IPMN, Main duct-IPMN, Mixed-IPMN), Mucinous cystic neoplasms, and Serous cystadenomas)
    • If surgery is not done, a chart review may be done for up to 5 years to follow the cyst over time.
  • Controls
    • Normal pancreas on EUS (or absence of features suggesting neoplasia)
    • No personal history of pancreatic neoplasia or of GI cancer at any level
    • Includes
      • Asymptomatic patients undergoing surveillance or diagnostic examination
        • Ideal group would be those undergoing EUS for evaluation of non-pancreatic lesions unlikely to shed luminal cells (e.g. small submucosal gastric lesions)
      • Patients with chronic dyspepsia (> 2 years), iron deficiency, or anemia
      • Patients with family history of pancreatic cancer
      • Patients with recurrent idiopathic pancreatitis or chronic pancreatitis found to have no lesions suspicious for pancreatic cancer on imaging

Exclusion Criteria

  • A positive pregnancy test
    • A pregnancy test will be obtained in premenopausal women agreeing to participate,and must be shown to be negative prior to endoscopy and secretin injection
  • Organ transplant
  • Pancreatic cancer is a recurrence
  • Received a chemotherapy class drug in past 6 months or are actively receiving one
  • Therapeutic radiation to esophagus or thorax/chest

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Ahlquist, M.D.

Closed for enrollment

Contact information:

Frances Cayer CCRP

Cayer.Frances@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Massimo Raimondo, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Rahul Pannala, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20492362

Mayo Clinic Footer